For more severe bronchiolitis, which therapy may be added?

For more severe bronchiolitis, which therapy may be added?

• A. Oral antibiotics
• B. Inhaled bronchodilators only
• C. IV hydration, ribavirin, RSV-IG prophylaxis
• D. No therapy

Answer: (C)

In more severe bronchiolitis, the management extends beyond basic supportive care to address dehydration, viral illness severity, and high-risk situations. Providing intravenous fluids helps correct dehydration from fever, poor intake, and increased respiratory effort. In infants with significant disease and risk factors (such as prematurity or underlying lung or heart disease), ribavirin—an antiviral targeting RSV—may be considered to help limit viral replication and potentially lessen illness severity, usually in a hospital or ICU setting. RSV immune globulin prophylaxis (RSV-IG) is used to reduce risk of RSV infection in high-risk infants during RSV season. It isn’t a treatment for an active infection in a hospitalized child, but it fits into the broader strategy of preventing severe disease in those most vulnerable. Together, these therapies reflect an approach that combines supportive care with targeted measures for those at greatest risk. Antibiotics aren’t routinely used unless there’s a suspected bacterial coinfection, and inhaled bronchodilators have limited and inconsistent evidence for benefit in severe bronchiolitis. No therapy wouldn’t be appropriate when severe disease is present.

In more severe bronchiolitis, the management extends beyond basic supportive care to address dehydration, viral illness severity, and high-risk situations. Providing intravenous fluids helps correct dehydration from fever, poor intake, and increased respiratory effort. In infants with significant disease and risk factors (such as prematurity or underlying lung or heart disease), ribavirin—an antiviral targeting RSV—may be considered to help limit viral replication and potentially lessen illness severity, usually in a hospital or ICU setting.

RSV immune globulin prophylaxis (RSV-IG) is used to reduce risk of RSV infection in high-risk infants during RSV season. It isn’t a treatment for an active infection in a hospitalized child, but it fits into the broader strategy of preventing severe disease in those most vulnerable. Together, these therapies reflect an approach that combines supportive care with targeted measures for those at greatest risk.

Antibiotics aren’t routinely used unless there’s a suspected bacterial coinfection, and inhaled bronchodilators have limited and inconsistent evidence for benefit in severe bronchiolitis. No therapy wouldn’t be appropriate when severe disease is present.